Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

Treated recipients received either 3 mg/kg rapamycin intraperitoneally for the first 14 d after transplantation (days 0-13) and/or 0.25 mg/dose CD40L-specific antibody (days 0, 2, 4, 7 and 10 ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

Merida has developed a novel platform to precisely target the pathogenic antibodies that underpin a wide array of autoimmune and allergic diseases. The company is developing antib ...

In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased ...

While DR-0201 clinical data has not been disclosed, Sanofi said it has “shown deep and robust B cell depletion in non-clinical and clinical settings.” Dren Bio’s lead candidate is DR-01, an antibody ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

Bispecific antibodies first reached patients as cancer ... These drugs were initially developed to treat blood cancers by depleting cancer-driving B cells. But B cells also drive certain ...